Lantyng Biotechnology

Lantyng Biotechnology is a synthetic biology company based in Hangzhou, China, that specializes in high-throughput screening and protein engineering for drug discovery. The company utilizes its proprietary Lantyng-HTS platform, which integrates microfluidics and automation, to rapidly identify and optimize functional peptides and proteins. Lantyng's primary therapeutic focus is on metabolic diseases, specifically the development of next-generation Glucagon-like peptide 1 receptor (GLP-1R) agonists for obesity and diabetes. By combining advanced molecular evolution techniques with synthetic biology, the company aims to streamline the transition from lead discovery to clinical development. Lantyng is backed by prominent venture capital firms including Qiming Venture Partners and Matrix Partners China.